RecruitingPhase 3NCT03773965
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Sponsor
Eli Lilly and Company
Enrollment
190 participants
Start Date
Apr 5, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Eligibility
Min Age: 1 YearMax Age: 18 Years
Inclusion Criteria1
- Participants must have completed a previous study of baricitinib for the treatment of JIA.
Exclusion Criteria2
- Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- Participants must have not developed an allergy to baricitinib.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBaricitinib
Administered orally.
Locations(82)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03773965
Related Trials
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT0299146929 locations
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
NCT072437821 location
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT0560963044 locations
Feasibility of a Diet Intervention for Juvenile Arthritis
NCT064745467 locations
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
NCT0622203410 locations